{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116475","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.049614+00:00","generated_at":"2026-06-22T02:33:48.951283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharma Q3 2022 loss widens to $8.6M; cash at $25.4M; SWARM-P.a. study near completion","bullets":["Loss from operations $(8.6)M in Q3 2022 vs $(6.1)M in Q3 2021, driven by higher R&D spending.","Cash and equivalents $25.4M as of Sept 30, 2022, up from $10.3M at Dec 31, 2021; expects $16.3M in MTEC grant funding.","R&D expenses $8.4M, up from $5.6M; G&A expenses $1.6M, down from $1.8M.","SWARM-P.a. Phase 2 MAD cohort enrollment finishing in Q4; top-line data expected early 2023.","AP-SA02 bacteremia study enrolling Phase 1b; regulatory approvals in Australia to accelerate enrollment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116475","json":"https://secwatch.observer/filing/0001104659-22-116475.json","markdown":"https://secwatch.observer/filing/0001104659-22-116475.md","text":"https://secwatch.observer/filing/0001104659-22-116475.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/0001104659-22-116475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/tm2226320d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:33:48.951283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50990689781bee35bef609a1bc39483fc7a37b54","claim":"Armata Pharmaceuticals, Inc. reported the three months ended September 30, 2022 results: revenue $1.3 million, net income $(8.6) million.","evidence_excerpt":"Third Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.3 million for the three months ended September 30, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia. The Company expects to receive $16.3 million in grant funding from MTEC administered by the U.S. Department of Defense and the Defense Health Agency and Joint Warfighter Medical Research Program. The Company recognized approximately $1.3 million of revenue in the comparable period in 2021. Research and Development. Research and development expenses for the three months ended September 30, 2022, were approximately $8.4 million as compared to approximately $5.6 million for the comparable period in 2021. The company continues to invest in clinical trial and personnel related expenses associated with its primary development programs. General an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465922116475/0001104659-22-116475-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$1.3 million"},{"label":"Net income","value":"$(8.6) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}